Compare TIC & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIC | AAPG |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | China |
| Employees | N/A | 567 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.8B |
| IPO Year | N/A | 2025 |
| Metric | TIC | AAPG |
|---|---|---|
| Price | $10.60 | $30.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.17 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 3.0M | 4.4K |
| Earning Date | 11-12-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,070,000.00 | $54,524,554.00 |
| Revenue This Year | $41.97 | N/A |
| Revenue Next Year | $42.94 | $368.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $8.76 | $16.50 |
| 52 Week High | $14.94 | $48.45 |
| Indicator | TIC | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 42.17 |
| Support Level | $9.24 | $28.50 |
| Resistance Level | $9.64 | $32.96 |
| Average True Range (ATR) | 0.43 | 0.70 |
| MACD | 0.24 | -0.05 |
| Stochastic Oscillator | 66.67 | 40.31 |
TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.